Ovid Therapeutics Inc. (OVID) financial statements and ratios from SEC XBRL: revenue $7.25M (TTM), net margin -240.1%, revenue growth 1181.3% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $7.25M |
| Net Margin | -240.1% |
| Revenue Growth (YoY) | 1181.3% |
| FCF Growth (YoY) | -31.6% |
| Price / Book | 2.60 |
| Price / Sales | 631.05 |
| FCF Yield | -5.1% |
| Altman Z-Score | 7.57 (safe) |
| Sector P/E (Healthcare) | 21.7 |
OVID overview · OVID earnings · OVID KPIs · OVID investor relations · OVID ownership · OVID peers · OVID filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.